ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
Home
Press release
Nov 29, 2022 19:28 JST
Source:
Eisai
Eisai Announces Approval of Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with Lewy Bodies
TOKYO, Nov 29, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced that its application for a partial change to label for Aricept (donepezil hydrochloride), a treatment for Alzheimer's disease and dementia with Lewy bodies (DLB) that was discovered and developed in-house, regarding dosage and administration for the treatment of DLB in Japan, has been approved today. (Please refer to "Notes to Editors" on the link below for details of the changes)
This partial change to label is based on the results of a reexamination for the indication of "suppression of progression of dementia symptoms in dementia with Lewy bodies" of this drug, which was categorized as Category 2.
After receiving approval for the partial change in dosage and administration for DLB, Eisai will continue to place the highest priority on the provision of proper use and safety information for this drug, and will make continued contributions to address the diversified needs of, and increase the benefits provided to people living with DLB and their families.
For more information visit www.eisai.com/news/2022/news202282.html.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech
Copyright ©2023 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Toyota Announces Changes to Organizational Structure and Senior Professionals/Senior Management
May 31, 2023 22:44 JST
MHI: Continuation of Maintenance of Manila MRT-3 in the Philippines
May 31, 2023 21:58 JST
Mitsubishi Motors to Unveil an All-New Compact SUV in Indonesia in August - Equipped with a New Automotive Sound System as a Collaboration with Yamaha
May 31, 2023 19:11 JST
Tokyo Kiraboshi FG and MC Sign Business Alliance Agreement
May 31, 2023 12:20 JST
Nissan, Mitsubishi Motors, and NMKV mark production of 50,000th fully electric minivehicle
May 31, 2023 11:56 JST
AWS Direct Connect location established at the NEC Inzai Data Center to create a hybrid cloud environment
May 31, 2023 11:04 JST
Daimler Truck, Mitsubishi Fuso, Hino and Toyota Motor Corporation conclude an MoU on accelerating development of Advanced Technologies and merging Mitsubishi Fuso and Hino Motors
May 30, 2023 20:15 JST
Mazda Production and Sales Results for April 2023
May 30, 2023 20:02 JST
Presto Partners VSING in Loyalty Points Collaboration
May 30, 2023 20:00 JST
Honda: Production, Sales and Export Results for April, 2023
May 30, 2023 16:06 JST
Toyota: Sales, Production, and Export Results for April 2023
May 30, 2023 15:12 JST
TANAKA Precious Metals to Exhibit at "Medtec China 2023" Medical Device Design and Manufacturing Exhibition, to be Held in Suzhou, China
May 30, 2023 15:00 JST
TANAKA Precious Metals to Exhibit at "Medtec China 2023" Medical Device Design and Manufacturing Exhibition, to be Held in Suzhou, China
May 30, 2023 15:00 JST
Shanghai MHI Engine Celebrates 10th Anniversary
May 30, 2023 14:32 JST
Fujitsu and Microsoft Announce Global Partnership to Enable "Sustainability Transformation"
May 30, 2023 14:03 JST
Olympus Names Wenlei Yang the Newly Established Chief Diversity, Equity and Inclusion Officer
May 29, 2023 15:00 JST
Olympus Names Wenlei Yang the Newly Established Chief Diversity, Equity and Inclusion Officer
May 29, 2023 15:00 JST
Toyota: Development and Verification of Stationary Storage Battery System Using Electric Vehicle Storage Batteries
May 29, 2023 13:31 JST
Mitsubishi Electric and Mitsubishi Heavy Industries Definitively Agree to Integrate Their Power-generator Systems Businesses
May 29, 2023 11:24 JST
Liquid Hydrogen-Powered Corolla to Participate in the Super Taikyu Fuji 24 Hours Race
May 29, 2023 09:08 JST
More Latest Release >>
Related Release
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
5/26/2023 2:15:00 PM JST
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria
5/25/2023 9:02:00 PM JST
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023
5/24/2023 6:03:00 PM JST
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Great Britain
5/20/2023 10:20:00 AM JST
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease
5/16/2023 9:27:00 AM JST
Eisai Enters Into Joint Development Agreement with Blissbio for Antibody Drug Conjugate BB-1701 with Option Rights for Strategic Collaboration
5/8/2023 11:15:00 AM JST
Eisai Completes a Major Renovation of Tsukuba Research Laboratories
4/6/2023 6:32:00 PM JST
Eisai Publishes Long-Term Health Outcomes Using Simulation Model of Lecanemab Using Phase 3 Clarity Ad Data in Peer-Reviewed Neurology and Therapy Journal
4/4/2023 1:23:00 PM JST
Eisai Enters Into Agreement With National Cancer Center to Collaborate on Investigator-Initiated Clinical Research for Anticancer Agent Tazemetostat Based on "Patient-Proposed Healthcare Services" System
4/3/2023 1:06:00 PM JST
Eisai Presented New Analyses of Aria and QOL on Lecanemab in Clarity AD at the AD/PD 2023 Annual Meeting
3/31/2023 4:51:00 PM JST
More Press release >>